摘要
目的探讨两种术后辅助化疗方案对卵巢癌患者的临床疗效及其对血清肿瘤标志物的影响。方法以2010年10月至2013年2月我院妇产科收治的60例卵巢癌患者为研究对象,依据肿瘤细胞减灭术后辅助化疗方案的不同,随机将患者分为顺铂+紫杉醇方案组(TP组)和环磷酰胺+博来霉素+卡铂组(CBP组),每组各30例,比较两种辅助化疗方案的临床治疗效果及肿瘤标志物的变化。结果 TP组的治疗总体有效率为83.33%,略高于CBP组的70.00%,但差异无统计学意义(χ2=1.491,P=0.222);两组患者的疾病控制率分别为96.67%和80.00%,TP组高于CBP组,差异有统计学意义(χ2=4.043,P=0.044);随访结果显示,TP组患者中位生存时间为14.0个月,略高于CBP组的11.9个月,但两组间经Log-rank检验比较差异无统计学意义(χ2=0.585,P=0.444);治疗后两组的血清肿瘤标志物均明显降低,其中CBP组患者的CYFRA21-1、CA125和CA19-9的降低幅度均明显高于TP组(P<0.05)。结论 TP和CBP化疗辅助方案对卵巢癌均具有良好的临床疗效,TP组疾病控制率高于CBP方案,但CBP方案对血清肿瘤标志物水平的影响更为显著。
Objective To explore the clinical effect of two different postoperative neoadjuvant chemotherapy on patients with ovarian cancer and their influence on serum levels of tumor markers. Methods Sixty cases of ovarian cancer from October 2010 to February 2013 in our hospital were selected as research objects and randomly divided into cisplatin ＋ paclitaxel group （ TP group） and cyclophosphamide ＋ bleomycin ＋ carboplatin group （ CBP group）,30 cases in each group. The curative effects of the two adjuvant chemotherapy and theirs influence on tumor markers were compared. Results After treatment,the overall effective rate of TP group was 83. 33%,showing slightly higher than that of CBP group （70. 00%）,but no significant difference was found between the two groups （χ2 =1. 491,P =0. 222）;and the disease control rate of both two groups were 96. 67%and 80. 00%,TP group was significantly higher than CBP group （ P =0. 044 ）;The follow-up results showed that the median survival time of TP group was 14. 0 months,which was slightly higher than that of CBP group （11. 9 months）,but the Log-rank test demonstrated that there was no significant difference between the two groups in survival time （χ2 =0. 585,P=0. 444）. After treatment,the ser-um tumor markers significantly decreased in two groups,and the decrease levels of CYFRA21-1,CA125 and CA19-9 of CBP group were significantly higher than those of TP group （ P〈0. 05 ） . Conclusion TP and CBP adjuvant chemo-therapy scheme have good clinical effect on cervical squamous cell carcinoma,the disease control rate of TP group is higher than CBP group,but the CBP scheme is more effective to improve the level of serum tumor markers.
出处
《实用药物与临床》
CAS
2015年第10期1181-1185,共5页
Practical Pharmacy and Clinical Remedies
关键词
卵巢癌
辅助化疗
血清肿瘤标志物
Ovarian cancer
Neoadjuvant chemotherapy
Tumor markers
